TWiV 941: Clinical update with Dr. Daniel Griffin

October 1, 2022

In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID.

Click arrow to play
Download TWiV 941 (30 MB .mp3, 50 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

Leave a Reply

Your email address will not be published. Required fields are marked *

One comment on “TWiV 941: Clinical update with Dr. Daniel Griffin

  1. Michelle Oct 1, 2022

    HAH! Did you both do rapid antigen tests before getting together for this broadcast? My friend tested positive the other day, and it was lucky I asked him to test b/c I’m waiting for surgery in a few weeks.